Friday, June 12, 2026
πŸ‡ΊπŸ‡Έ FDA

Patent directory Β· USPTO A61K / A61P

Browse patents

Browse 30,257 pharma-relevant patents (US A61K/A61P) linked to tracked companies, drugs, and pipeline programs.

Patents indexed 30,257
Companies 1,769
Drugs linked 4,797

Quick answer

NovaPharmaNews indexes 30,257 US pharmaceutical patents from USPTO PatentsView (CPC A61K/A61P), cross-linked to company assignees, drug INN profiles, and pipeline programs. Search by patent number, applicant, title, or CPC code β€” or use facet hubs for expiring patents, assignees, and therapeutic areas.

Patent results

Page 1114 of 1,261

  1. AU 2001281846

    Method for preparing a composition

    CHEPLAPHARM ARZNEIMITTEL GMBH [DE] Β· Granted Apr 27, 2006 Β· Expires Apr 22, 2026

    expired

  2. US 7033603

    Drug releasing biodegradable fiber for delivery of therapeutics

    The Board of Regents of the University of Texas Β· Granted Apr 25, 2006 Β· Expires Apr 20, 2026

    expired

  3. US 7034016

    8-phenyl-6,9-dihydro-[1,2,4]triazolo[3,4-i]purin-5-one derivatives

    Almirall Prodesfarma S.A. Β· Granted Apr 25, 2006 Β· Expires Apr 20, 2026

    expired

  4. US 7033750

    Recombinant P53 adenovirus methods and compositions

    The Board of Regents of the University of Texas System Β· Granted Apr 25, 2006 Β· Expires Apr 20, 2026

    expired

  5. US 7034014

    Phosphonate compounds

    The Regents of the University of California Β· Granted Apr 25, 2006 Β· Expires Apr 20, 2026

    expired

  6. US 7034056

    Aryl and biaryl compounds having MCH modulatory activity

    Pharmacopeia Drug Discovery, Inc. Β· Granted Apr 25, 2006 Β· Expires Apr 20, 2026

    expired

  7. US 7034048

    Gastrin and cholecystokinin receptor ligands (III)

    The James Black Foundation Limited Β· Granted Apr 25, 2006 Β· Expires Apr 20, 2026

    expired

  8. US 7034118

    Corticotropin-releasing factor2 receptors

    Neurocrine Biosciences, Inc. Β· Granted Apr 25, 2006 Β· Expires Apr 20, 2026

    expired

  9. US 7034039

    Fused heterocyclic compounds

    Takeda Pharmaceutical Company Limited Β· Granted Apr 25, 2006 Β· Expires Apr 20, 2026

    expired

  10. US 7033771

    Use of insulin response modulators in the treatment of diabetes and insulin resistance

    Takeda Pharmaceutical Company Limited Β· Granted Apr 25, 2006 Β· Expires Apr 20, 2026

    expired

  11. US 7033620

    Product and process for stabilizing Aloe vera gel

    Aloe Vera of America, Inc. Β· Granted Apr 25, 2006 Β· Expires Apr 20, 2026

    expired

  12. US 7033608

    β€œBurst-free” sustained release poly-(lactide/glycolide) microspheres

    The United States of America as represented by the Secretary of the Army Β· Granted Apr 25, 2006 Β· Expires Apr 20, 2026

    expired

  13. US 7033582

    Use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders

    TEVA PHARMACEUTICAL INDUSTRIES, LTD. Β· Granted Apr 25, 2006 Β· Expires Apr 20, 2026

    expired

  14. US 7030087

    Synthetic approach to designed chemical structures

    Regents of the University of Minnesota Β· Granted Apr 18, 2006 Β· Expires Apr 13, 2026

    expired

  15. US 7030231

    Membrane type serine protease 1 (MT-SP1) and uses thereof

    Catalyst Biosciences, Inc. Β· Granted Apr 18, 2006 Β· Expires Apr 13, 2026

    expired

  16. US 7030080

    Lymphotoxin-Ξ², lymphotoxin-Ξ² complexes, pharmaceutical preparations and therapeutic uses thereof

    The Regents of the University of California Β· Granted Apr 18, 2006 Β· Expires Apr 13, 2026

    expired

  17. US 7029911

    AFC1 and RCE1: isoprenylated CAAX processing enzymes

    The Regents of the University of California Β· Granted Apr 18, 2006 Β· Expires Apr 13, 2026

    expired

  18. US 7029838

    Prevascularized contructs for implantation to provide blood perfusion

    Arizona Board of Regents on Behalf of the University of Arizona Β· Granted Apr 18, 2006 Β· Expires Apr 13, 2026

    expired

  19. US 7030278

    Polyethylene(Glycol) derivatives with proximal reactive groups

    Nektar Therapeutics AL, Corporation Β· Granted Apr 18, 2006 Β· Expires Apr 13, 2026

    expired

  20. US 7029696

    Delivery and activation through liposome incorporation of diaminocyclohexane platinum(II) complexes

    The Board of Regents of the University of Texas System Β· Granted Apr 18, 2006 Β· Expires Apr 13, 2026

    expired

  21. US 7029652

    Method of treating tumors

    The Regents of the University of California Β· Granted Apr 18, 2006 Β· Expires Apr 13, 2026

    expired

  22. US 7030232

    E25A protein, methods for producing and use thereof

    The Regents of the University of California Β· Granted Apr 18, 2006 Β· Expires Apr 13, 2026

    expired

  23. US 7029685

    Plasmodium falciparum AMA-1 protein and uses thereof

    The United States of America as represented by the Secretary of the Army Β· Granted Apr 18, 2006 Β· Expires Apr 13, 2026

    expired

  24. US 7029899

    Selective toxicity of amino-terminal modified rnase a superfamily polypeptides

    The United States of America, as represented by the Department of Health and Human Services Β· Granted Apr 18, 2006 Β· Expires Apr 13, 2026

    expired

Frequently asked questions

What patents are included in this directory?

We index 30,257 published US pharma-relevant patents filtered to CPC classes A61K and A61P, with assignee links to our company directory where a match exists.

How do I search for a patent?

Use the search box to match patent number, title, applicant name, or CPC classification (e.g. A61K). For cross-entity queries spanning news and drugs, use the global search.

How is this different from the patent intelligence dashboard?

The dashboard at /patents highlights expirations, recent grants, and assignee rankings. Browse is the full paginated directory with search β€” best for looking up a specific filing or applicant portfolio slice.

Drug approvals, clinical trials, M&A, event intelligence, and company updates β€” weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.